Abstract：
BACKGROUND: Considering the role of adipokine on diseases related to metabolic syndrome and even chronic diseases, it seems necessary to investigate effective interventions on these factors. This study aimed to comprehensively investigate the effects of metformin on adipokines.
METHODS: A comprehensive search was conducted in five databases using established keywords. The purpose of this search was to uncover controlled studies that have examined the impact of metformin on adipokines, specifically leptin, adiponectin, and resistin. The random-effects model analysis was used to provide pooled weighted mean difference and 95% confidence intervals.
RESULTS: Forty-nine studies were included in this article. The pooled findings showed that that the administration of metformin significantly decreases leptin (WMD: -3.06 ng/ml, 95 % CI: -3.81, -2.30, P < 0.001) and resistin (WMD: -1.27 µg/mL, 95 % CI: -2.22, -0.31, P = 0.009) levels in different populations compared to the control group. However, no significant effect of this antidiabetic drug on adiponectin levels was reported. The results obtained from the subgroup results in the present study also showed that metformin in people with a BMI greater than 30 kg/m2 compared to a BMI ≤ 30 kg/m2 causes a significant decrease in leptin levels and an increase in adiponectin levels. Also, metformin in lower doses (≤1500 mg/day) and younger people (<30 years) causes a significant increase in adiponectin levels.
CONCLUSIONS: In general, considering the role of adipokines on metabolic disease and even chronic disease, this drug can be used as a potentially useful drug, especially in obese people, to improve these factors.
METHODS: A comprehensive search was conducted in five databases using established keywords. The purpose of this search was to uncover controlled studies that have examined the impact of metformin on adipokines, specifically leptin, adiponectin, and resistin. The random-effects model analysis was used to provide pooled weighted mean difference and 95% confidence intervals.
RESULTS: Forty-nine studies were included in this article. The pooled findings showed that that the administration of metformin significantly decreases leptin (WMD: -3.06 ng/ml, 95 % CI: -3.81, -2.30, P < 0.001) and resistin (WMD: -1.27 µg/mL, 95 % CI: -2.22, -0.31, P = 0.009) levels in different populations compared to the control group. However, no significant effect of this antidiabetic drug on adiponectin levels was reported. The results obtained from the subgroup results in the present study also showed that metformin in people with a BMI greater than 30 kg/m2 compared to a BMI ≤ 30 kg/m2 causes a significant decrease in leptin levels and an increase in adiponectin levels. Also, metformin in lower doses (≤1500 mg/day) and younger people (<30 years) causes a significant increase in adiponectin levels.
CONCLUSIONS: In general, considering the role of adipokines on metabolic disease and even chronic disease, this drug can be used as a potentially useful drug, especially in obese people, to improve these factors.
摘要：
背景：考虑到脂肪因子在与代谢综合征甚至慢性疾病有关的疾病中的作用，似乎有必要研究对这些因素的有效干预措施。本研究旨在全面探讨二甲双胍对脂肪因子的影响。
方法：使用已建立的关键字在五个数据库中进行了全面搜索。这项研究的目的是发现研究二甲双胍对脂肪因子影响的对照研究。特别是瘦素,脂联素,和抵抗素。随机效应模型分析用于提供合并加权平均差和95%置信区间。
结果：本文纳入了49项研究。汇总结果显示，二甲双胍的给药可显著降低瘦素（WMD：-3.06ng/ml，95%CI：-3.81，-2.30，P<0.001）和抵抗素（WMD：-1.27µg/mL，与对照组相比，95％CI：-2.22，-0.31，P=0.009）在不同人群中的水平。然而,没有报道该抗糖尿病药物对脂联素水平的显著影响.从本研究的亚组结果获得的结果还表明，与BMI≤30kg/m2相比，BMI大于30kg/m2的人中的二甲双胍会导致瘦素水平显着降低和脂联素水平升高。此外，二甲双胍在较低剂量(≤1500毫克/天)和年轻人(<30岁)时导致脂联素水平显著升高。
结论：一般来说，考虑到脂肪因子在代谢性疾病甚至慢性疾病中的作用，这种药物可以用作潜在有用的药物，尤其是在肥胖人群中，改善这些因素。
方法：使用已建立的关键字在五个数据库中进行了全面搜索。这项研究的目的是发现研究二甲双胍对脂肪因子影响的对照研究。特别是瘦素,脂联素,和抵抗素。随机效应模型分析用于提供合并加权平均差和95%置信区间。
结果：本文纳入了49项研究。汇总结果显示，二甲双胍的给药可显著降低瘦素（WMD：-3.06ng/ml，95%CI：-3.81，-2.30，P<0.001）和抵抗素（WMD：-1.27µg/mL，与对照组相比，95％CI：-2.22，-0.31，P=0.009）在不同人群中的水平。然而,没有报道该抗糖尿病药物对脂联素水平的显著影响.从本研究的亚组结果获得的结果还表明，与BMI≤30kg/m2相比，BMI大于30kg/m2的人中的二甲双胍会导致瘦素水平显着降低和脂联素水平升高。此外，二甲双胍在较低剂量(≤1500毫克/天)和年轻人(<30岁)时导致脂联素水平显著升高。
结论：一般来说，考虑到脂肪因子在代谢性疾病甚至慢性疾病中的作用，这种药物可以用作潜在有用的药物，尤其是在肥胖人群中，改善这些因素。
